āĻšā§‹āĻŽI7G â€ĸ FRA
Ipsen SA
⧝⧝.ā§Ēā§Ļâ‚Ŧ
ā§Šā§Ļ āĻāĻĒā§āϰāĻŋ, ā§§ā§Ļ:ā§Ģ⧝:ā§Ēā§Ē PM GMT +⧍ · EUR · FRA · āĻĄāĻŋāϏāĻ•ā§āϞ⧇āĻŽāĻžāϰ
āĻ¸ā§āϟāĻ•DE-āĻ āϤāĻžāϞāĻŋāĻ•āĻžāϭ⧁āĻ•ā§āϤ āϏāĻŋāĻ•āĻŋāωāϰāĻŋāϟāĻŋ
āĻ•āĻžāϞ āĻļ⧇āώ āϝ⧇ āĻĻāĻžāĻŽā§‡ āĻ›āĻŋāϞ
ā§¯ā§Ž.ā§­ā§Ģâ‚Ŧ
āϏāĻžāϰāĻž āĻĻāĻŋāύ⧇āϰ āĻŸā§āϰ⧇āĻĄāĻŋāĻ‚ā§Ÿā§‡ āĻ¸ā§āϟāϕ⧇āϰ āĻĻāĻžāĻŽā§‡āϰ āĻ“āĻ āĻž āύāĻžāĻŽāĻžāϰ āϰ⧇āĻžā§āϜ
⧝⧝.ā§Ēā§Ļâ‚Ŧ - ⧝⧝.ā§Ēā§Ļâ‚Ŧ
āϏāĻžāϰāĻž āĻŦāĻ›āϰ⧇āϰ āϰ⧇āĻžā§āϜ
⧝ā§Ļ.⧍ā§Ļâ‚Ŧ - ⧧⧍ā§Ģ.ā§Šā§Ļâ‚Ŧ
āĻŽāĻžāĻ°ā§āϕ⧇āϟ āĻ•ā§āϝāĻžāĻĒ
ā§Žā§Ēā§Š.⧍ā§Ē āϕ⧋ EUR
āĻ—āĻĄāĻŧ āĻ­āϞāĻŋāωāĻŽ
ā§Ē.ā§Ļā§Ļ
P/E āĻ…āύ⧁āĻĒāĻžāϤ
ā§¨ā§Š.⧍⧝
āϞāĻ­ā§āϝāĻžāĻ‚āĻļ āĻĒā§āϰāĻĻāĻžāύ
ā§§.ā§Ēā§§%
āĻĒā§āϰāĻžāχāĻŽāĻžāϰāĻŋ āĻāĻ•ā§āϏāĻšā§‡āĻžā§āϜ
EPA
āĻŦāĻžāϜāĻžāϰ āϏāĻ‚āĻŦāĻžāĻĻ
.INX
ā§§.⧍ā§Ē%
VOO
ā§§.ā§Šā§Ē%
META
ā§Ģ.ā§Šā§¨%
MSFT
ā§Ž.⧝⧝%
NDAQ
ā§Ļ.ā§Ģā§§%
.DJI
ā§Ļ.ā§Ŧā§­%
.DJI
ā§Ļ.ā§Ŧā§­%
META
ā§Ģ.ā§Šā§¨%
MSFT
ā§Ž.⧝⧝%
NDAQ
ā§Ļ.ā§Ģā§§%
.INX
ā§§.⧍ā§Ē%
META
ā§Ģ.ā§Šā§¨%
MSFT
ā§Ž.⧝⧝%
NDAQ
ā§Ļ.ā§Ģā§§%
āĻĢāĻžāχāύāĻžāĻ¨ā§āϏāĻŋ⧟āĻžāϞ āĻĒāĻžāϰāĻĢāĻ°ā§āĻŽā§āϝāĻžāĻ¨ā§āϏ
āĻ†ā§Ÿā§‡āϰ āĻ¸ā§āĻŸā§‡āϟāĻŽā§‡āĻ¨ā§āϟ
āωāĻĒāĻžāĻ°ā§āϜāύ
āύ⧇āϟ āχāύāĻ•āĻžāĻŽ
(EUR)āĻĄāĻŋāϏ⧇ ⧍ā§Ļ⧍ā§ĒY/Y āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ
āωāĻĒāĻžāĻ°ā§āϜāύ
⧝⧧.ā§§ā§Ē āĻ•ā§‹â€”
āĻŦā§āϝāĻŦāϏāĻž āϚāĻžāϞāĻžāύ⧋āϰ āĻ–āϰāϚ
ā§Ģā§Ļ.ā§§ā§Ļ āĻ•ā§‹â€”
āύ⧇āϟ āχāύāĻ•āĻžāĻŽ
ā§Ģ.ā§­ā§Ļ āĻ•ā§‹â€”
āύ⧇āϟ āĻĒā§āϰāĻĢāĻŋāϟ āĻŽāĻžāĻ°ā§āϜāĻŋāύ
ā§Ŧ.⧍ā§Ģ—
āĻļā§‡ā§ŸāĻžāϰ āĻĒā§āϰāϤāĻŋ āωāĻĒāĻžāĻ°ā§āϜāύ
——
EBITDA
ā§Šā§Ģ.ā§Ēā§¯Â āĻ•ā§‹â€”
āĻĒā§āϰāϝ⧋āĻœā§āϝ āĻŸā§āϝāĻžāĻ•ā§āϏ⧇āϰ āĻšāĻžāϰ
⧧⧝.ā§Ēā§§%—
āĻŽā§‹āϟ āϏāĻŽā§āĻĒāĻĻ
āĻŽā§‹āϟ āĻĻāĻžā§Ÿ
(EUR)āĻĄāĻŋāϏ⧇ ⧍ā§Ļ⧍ā§ĒY/Y āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ
āĻ•ā§āϝāĻžāĻļ āĻ“ āĻ•āĻŽ āϏāĻŽā§Ÿā§‡āϰ āĻŦāĻŋāύāĻŋā§Ÿā§‹āĻ—
ā§Ŧā§­.ā§¯ā§¨Â āĻ•ā§‹ā§¨ā§Ž.ā§Ģā§Ē%
āĻŽā§‹āϟ āϏāĻŽā§āĻĒāĻĻ
ā§Ŧā§Ēā§Š.⧝ā§Ļ āϕ⧋⧧.ā§Žā§Ē%
āĻŽā§‹āϟ āĻĻāĻžā§Ÿ
⧍⧍ā§Ģ.ā§­ā§¨Â āϕ⧋-⧝.ā§Ŧā§Ž%
āĻŽā§‹āϟ āχāϕ⧁āχāϟāĻŋ
ā§Ēā§§ā§Ž.ā§§ā§ŽÂ āĻ•ā§‹â€”
āφāωāϟāĻ¸ā§āĻŸā§āϝāĻžāĻ¨ā§āĻĄāĻŋāĻ‚ āĻļā§‡ā§ŸāĻžāϰ
ā§Ž.ā§¨ā§­Â āĻ•ā§‹â€”
āĻĒā§āϰāĻžāχāϏ āϟ⧁ āĻŦ⧁āĻ• āϰ⧇āĻļāĻŋāĻ“
ā§§.⧝ā§Ģ—
āϏāĻŽā§āĻĒāĻĻ āĻĨ⧇āϕ⧇ āĻ†ā§Ÿ
ā§§ā§Ļ.ā§Ļā§­%—
āĻŽā§‚āϞāϧāύ āĻĨ⧇āϕ⧇ āĻ†ā§Ÿ
ā§§ā§Š.ā§Žā§Ļ%—
āύāĻ—āĻĻ⧇ āĻŽā§‹āϟ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ
(EUR)āĻĄāĻŋāϏ⧇ ⧍ā§Ļ⧍ā§ĒY/Y āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ
āύ⧇āϟ āχāύāĻ•āĻžāĻŽ
ā§Ģ.ā§­ā§Ļ āĻ•ā§‹â€”
āĻ…āĻĒāĻžāϰ⧇āĻļāύ āĻĨ⧇āϕ⧇ āĻĒāĻžāĻ“ā§ŸāĻž āĻ•ā§āϝāĻžāĻļ
⧍⧍.ā§Ēā§ŽÂ āĻ•ā§‹â€”
āĻŦāĻŋāύāĻŋā§Ÿā§‹āĻ— āĻĨ⧇āϕ⧇ āĻĒā§āϰāĻžāĻĒā§āϤ āĻ•ā§āϝāĻžāĻļ
-ā§¨ā§Š.ā§Žā§ŽÂ āĻ•ā§‹â€”
āĻĢāĻžāχāĻ¨ā§āϝāĻžāĻ¨ā§āϏāĻŋāĻ‚ āĻĨ⧇āϕ⧇ āĻĒā§āϰāĻžāĻĒā§āϤ āĻ•ā§āϝāĻžāĻļ
ā§§ā§Ļ.ā§¯ā§§Â āĻ•ā§‹â€”
āύāĻ—āĻĻ⧇ āĻŽā§‹āϟ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ
ā§§ā§Ļ.ā§Ģā§Ļ āĻ•ā§‹â€”
āĻĢā§āϰāĻŋ āĻ•ā§āϝāĻžāĻļ āĻĢā§āϞ⧋
ā§Ŧ.ā§Žā§­Â āĻ•ā§‹â€”
āϏāĻŽā§āĻĒāĻ°ā§āϕ⧇
Ipsen is a French biopharmaceutical company headquartered in Paris, France, with a focus on drug development and commercialization in three therapeutic areas: oncology, rare diseases and neuroscience. Ipsen is one of the world's top 15 biopharmaceutical companies in terms of oncology sales. Ipsen, founded by Henri Beaufour in 1929, has approximately 5000 employees worldwide. Ipsen's medicines are registered in 88 countries with direct commercial presence in over 30 countries. Ipsen has 4 global R&D hubs and 3 pharmaceutical development centers around the world. Ipsen has been a family-owned business for the past 90 years and is publicly traded on the Euronext Paris as part of the SBF 120 index. The Beaufour family owns 57% of its shares and 73% of its voting rights, and two of its members, Anne Beaufour and Henri Beaufour, sit on its board of directors. Wikipedia
āĻ¸ā§āĻĨāĻžāĻĒāĻŋāϤ āĻšā§Ÿā§‡āϛ⧇
⧧⧝⧍⧝
āĻ“ā§Ÿā§‡āĻŦāϏāĻžāχāϟ
āĻ•āĻ°ā§āĻŽāϚāĻžāϰ⧀
ā§Ģ,ā§Šā§Ģā§Ž
āφāϰāĻ“ āĻĻ⧇āϖ⧁āύ
āφāĻĒāύāĻžāϰ āĻšā§ŸāϤ āĻĒāĻ›āĻ¨ā§āĻĻ āĻšāĻŦ⧇
āϏāĻŽā§āĻĒā§āϰāϤāĻŋ āĻ•āϰāĻž āϏāĻžāĻ°ā§āϚ, āĻĢāϞ⧋ āĻ•āϰāĻž āϏāĻŋāĻ•āĻŋāωāϰāĻŋāϟāĻŋ āĻāĻŦāĻ‚ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ…ā§āϝāĻžāĻ•ā§āϟāĻŋāĻ­āĻŋāϟāĻŋ āĻĨ⧇āϕ⧇ āĻāχ āϤāĻžāϞāĻŋāĻ•āĻžāϟāĻŋ āĻœā§‡āύāĻžāϰ⧇āϟ āĻ•āϰāĻž āĻšā§Ÿā§‡āϛ⧇āĨ¤ āφāϰāĻ“ āϜāĻžāύ⧁āύ

āϏāĻŽāĻ¸ā§āϤ āĻĄā§‡āϟāĻž āĻ“ āϤāĻĨā§āϝ "āϝ⧇āĻŽāύāĻ­āĻžāĻŦ⧇ āĻĒāĻžāĻ“ā§ŸāĻž āϗ⧇āϛ⧇, āĻ āĻŋāĻ• āϤ⧇āĻŽāύāĻ­āĻžāĻŦ⧇" āĻļ⧁āϧ⧁āĻŽāĻžāĻ¤ā§āϰ āĻŦā§āϝāĻ•ā§āϤāĻŋāĻ—āϤ āϤāĻĨā§āϝ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ⧇ āĻĒā§āϰāĻĻāĻžāύ āĻ•āϰāĻž āĻšā§Ÿā§‡āϛ⧇ āĻāĻŦāĻ‚ āĻļā§‡ā§ŸāĻžāϰ āĻŸā§āϰ⧇āĻĄāĻŋāĻ‚ āĻŦāĻž āĻĢāĻžāχāĻ¨ā§āϝāĻžāĻ¨ā§āϏāĻŋ⧟āĻžāϞ, āĻŦāĻŋāύāĻŋā§Ÿā§‹āĻ—, āĻŸā§āϝāĻžāĻ•ā§āϏ, āφāχāύāĻŋ āĻŦāĻŋāώ⧟, āĻ…ā§āϝāĻžāĻ•āĻžāωāĻ¨ā§āϟāĻŋāĻ‚ āĻŦāĻž āĻ…āĻ¨ā§āϝ āϕ⧋āύāĻ“ āĻĒāϰāĻžāĻŽāĻ°ā§āĻļ āĻŦāĻž āωāĻĒāĻĻ⧇āĻļ āĻĻ⧇āĻ“ā§ŸāĻžāϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ⧇ āϤāĻž āĻ•āϰāĻž āĻšā§ŸāύāĻŋāĨ¤ Google āϕ⧋āύāĻ“ āĻŦāĻŋāύāĻŋā§Ÿā§‹āĻ— āϏāĻ‚āĻ•ā§āϰāĻžāĻ¨ā§āϤ āĻŦāĻž āĻĢāĻžāχāĻ¨ā§āϝāĻžāĻ¨ā§āϏāĻŋ⧟āĻžāϞ āωāĻĒāĻĻ⧇āĻˇā§āϟāĻž āύ⧟ āĻāĻŦāĻ‚ āĻāχ āϤāĻžāϞāĻŋāĻ•āĻžāϤ⧇ āĻ…āĻ¨ā§āϤāĻ°ā§āϭ⧁āĻ•ā§āϤ āϕ⧋āĻŽā§āĻĒāĻžāύāĻŋ āĻ…āĻĨāĻŦāĻž āϏ⧇āχāϏāĻŦ āϕ⧋āĻŽā§āĻĒāĻžāύāĻŋāϰ āχāĻ¸ā§āϝ⧁ āĻ•āϰāĻž āϏāĻŋāĻ•āĻŋāωāϰāĻŋāϟāĻŋāϰ āĻŦā§āϝāĻžāĻĒāĻžāϰ⧇ āϕ⧋āύāĻ“ āϰāĻ•āĻŽ āĻŽāϤāĻžāĻŽāϤ āĻŦā§āϝāĻ•ā§āϤ āĻ•āϰ⧇ āύāĻžāĨ¤ āϝ⧇āϕ⧋āύāĻ“ āϧāϰāύ⧇āϰ āĻŸā§āϰ⧇āĻĄ āĻ•āϰāĻžāϰ āφāϗ⧇, āĻŽā§‚āĻ˛ā§āϝ āϝāĻžāϚāĻžāχ āĻ•āϰ⧇ āύ⧇āĻ“ā§ŸāĻžāϰ āϜāĻ¨ā§āϝ āφāĻĒāύāĻžāϰ āĻŦā§āϰ⧋āĻ•āĻžāϰ āĻŦāĻž āĻĢāĻžāχāĻ¨ā§āϝāĻžāĻ¨ā§āϏāĻŋ⧟āĻžāϞ āĻĒā§āϰāϤāĻŋāύāĻŋāϧāĻŋāϰ āϏāĻžāĻĨ⧇ āφāϞ⧋āϚāύāĻž āĻ•āϰ⧇ āύāĻŋāύāĨ¤ āφāϰāĻ“ āϜāĻžāύ⧁āύ
āϏāĻžāĻ°ā§āϚ āĻ•āϰ⧁āύ
āϏāĻžāĻ°ā§āϚ āĻŽā§āϛ⧁āύ
āϏāĻžāĻ°ā§āϚ āĻŦāĻ¨ā§āϧ āĻ•āϰ⧁āύ
Google āĻ…ā§āϝāĻžāĻĒā§āϞāĻŋāϕ⧇āĻļāĻžāύāϗ⧁āϞāĻŋ
āĻĒā§āϰāϧāĻžāύ āĻŽā§‡āύ⧁